Understanding the new Psoriasis Treatment Guidelines

NPF and the American Academy of Dermatology have released two sections of the new guidelines outlining best practices for managing psoriasis. The guidelines, which were published online in the Journal of the American Academy of Dermatology in February 2019, were developed by an expert group composed of dermatologists, a cardiologist, a rheumatologist and patient representatives.

The two guidelines sections relate to biologics and comorbidities. There will be four more. Together, they represent the first updating of psoriasis treatment guidelines in a decade. They will provide health care professionals, patients, insurers and caregivers with the most accurate, up-to-date, evidence-based approaches for treating people with psoriasis.

The top two recommendations:

Biologics

The majority of people with mild-to-moderate psoriasis are capable of controlling their disease with topical medications or phototherapy. However, this approach may be insufficient for anyone with moderate-to-severe psoriasis. Biologics, which have a high benefit-to-risk ratio, may be more successful.

Comorbidities

Among the comorbidities associated with psoriasis are psoriatic arthritis (PsA), cardiovascular disease (diseases of the heart and arteries), metabolic syndrome (including type 2 diabetes) and mental health (depression and anxiety). Doctors and patients should be aware of the need to look for psoriatic joint disease at each visit as well as potential problems from other conditions. Patients should know that making simple lifestyle changes may be beneficial.

In 2019, the AAD/NPF team will publish further sections of the guidelines:

Follow the links below to learn more.